Share：
Share this content in WeChat
X
[Chinese] [PDF] 67 2
• Review •
Research progress on radiomics-based precise subtyping and risk stratification of intrahepatic cholangiocarcinoma
SUN Ziyue  GUO Shicheng  GU Siming  YIN Xiaoping 

DOI:10.12015/issn.1674-8034.2026.07.026.


[Abstract] Intrahepatic cholangiocarcinoma (ICC) is a highly malignant type of primary liver cancer characterized by a high risk of recurrence. This tumor exhibits significant heterogeneity, which profoundly influences patient prognosis and therapeutic response. Radiomics enables the non-invasive quantification of microscopic tumor features. By integrating multidimensional data, including pathological and genomic information, predictive models can be constructed to assist in diagnosis, targeted therapy, and surgical planning. Current research is predominantly retrospective, and a lack of standardized criteria for tumor subregional segmentation often leads to indirect biological interpretation of features. Future efforts should focus on integrating multimodal imaging with deep learning to elucidate the biological significance of the peritumoral microenvironment. Furthermore, multi-center prospective studies are essential to enhance model generalizability. This review summarizes the latest advancements in deciphering the pathological subtypes, molecular characteristics, and invasiveness of ICC using radiomics, offering new perspectives for achieving non-invasive risk stratification and personalized treatment.
[Keywords] intrahepatic cholangiocarcinoma；tumor heterogeneity；molecular subtype；radiomics；magnetic resonance imaging

SUN Ziyue1, 2   GUO Shicheng1, 2   GU Siming1, 2   YIN Xiaoping1, 2*  

1 Department of Radiology, Affiliated Hospital of Hebei University, Baoding 071000, China

2 Hebei Key Laboratory of Precise Imaging of Inflammation Related Tumors, Baoding 071000, China

Corresponding author: YIN X P, E-mail: yinxiaoping78@sina.com

Conflicts of interest   None.

Received  2026-02-24
Accepted  2026-05-14
DOI: 10.12015/issn.1674-8034.2026.07.026
DOI:10.12015/issn.1674-8034.2026.07.026.

[1]
CHANG Y J, CHANG Y J, CHEN L J. Prognostic factors in patients with intrahepatic cholangiocarcinoma[J/OL]. Sci Rep, 2024, 14: 19084 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/39154139/. DOI: 10.1038/s41598-024-70124-z.
[2]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[3]
MORIS D, PALTA M, KIM C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians[J]. CA Cancer J Clin, 2023, 73(2): 198-222. DOI: 10.3322/caac.21759.
[4]
GRANATA V, FUSCO R, DE MUZIO F, et al. Risk assessment and cholangiocarcinoma: diagnostic management and artificial intelligence[J/OL]. Biology, 2023, 12(2): 213 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/36829492/. DOI: 10.3390/biology12020213.
[5]
LI F W, LI Y, WANG L S, et al. Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: a study based on single-cell and spatial transcriptomic sequencing[J]. Hepatology, 2026, 83(5): 1082-1097. DOI: 10.1097/HEP.0000000000001423.
[6]
PORRECA V, BARBAGALLO C, CORBELLA E, et al. Unveil intrahepatic cholangiocarcinoma heterogeneity through the lens of omics and multi-omics approaches[J/OL]. Cancers, 2024, 16(16): 2889 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/39199659/. DOI: 10.3390/cancers16162889.
[7]
CERRITO L, AINORA M E, BORRIELLO R, et al. Contrast-enhanced imaging in the management of intrahepatic cholangiocarcinoma: state of art and future perspectives[J/OL]. Cancers, 2023, 15(13): 3393 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37444503/. DOI: 10.3390/cancers15133393.
[8]
CIRESA M, DE GAETANO A M, POMPILI M, et al. Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at Multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features[J]. Eur Rev Med Pharmacol Sci, 2015, 19(15): 2786-2797.
[9]
HUANG H Z, CHEN F. Molecular and histological profiles and relevant imaging signatures of intrahepatic cholangiocarcinoma[J]. J Clin Transl Hepatol, 2025, 13(6): 504-515. DOI: 10.14218/JCTH.2024.00410.
[10]
KOVAČ J D, JANKOVIĆ A, ĐIKIĆ-ROM A, et al. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: how to differentiate them using MRI[J]. Curr Oncol, 2022, 29(2): 698-723. DOI: 10.3390/curroncol29020061.
[11]
CARPINO G, OVERI D, MACIAS R I R, et al. Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement[J]. Hepatology, 2026, 83(4): 753-770. DOI: 10.1097/hep.0000000000001425.
[12]
CHEN S, ZHU Y M, WAN L J, et al. Predicting the microvascular invasion and tumor grading of intrahepatic mass-forming cholangiocarcinoma based on magnetic resonance imaging radiomics and morphological features[J]. Quant Imaging Med Surg, 2023, 13(12): 8079-8093. DOI: 10.21037/qims-23-11.
[13]
YANG S Q, HU H J, HU Y F, et al. Is tumor necrosis a clinical prognostic factor in hepato-biliary-pancreatic cancers A systematic review and meta-analysis[J]. Cancer Med, 2023, 12(10): 11166-11176. DOI: 10.1002/cam4.5742.
[14]
ZHUO L Y, CHEN W J, XING L H, et al. MRI-based quantification of intratumoral heterogeneity for intrahepatic mass-forming cholangiocarcinoma grading: a multicenter study[J/OL]. Insights Imaging, 2025, 16(1): 101 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/40369381/. DOI: 10.1186/s13244-025-01985-9.
[15]
WANG S P, WANG X H, YIN X P, et al. Differentiating HCC from ICC and prediction of ICC grade based on MRI deep-radiomics: Using lesions and their extended regions[J/OL]. Phys Med, 2024, 120: 103322 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/38452430/. DOI: 10.1016/j.ejmp.2024.103322.
[16]
FIZ F, ROSSI N, LANGELLA S, et al. Radiomic analysis of intrahepatic cholangiocarcinoma: non-invasive prediction of pathology data: a multicenter study to develop a clinical-radiomic model[J/OL]. Cancers, 2023, 15(17): 4204 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37686480/. DOI: 10.3390/cancers15174204.
[17]
LI X M, XING L H, ZHUO L Y, et al. Development and validation of a model for predicting pathological grade of intrahepatic mass-forming cholangiocarcinoma based on intratumoral and peritumoral features on MRI[J]. Chin J Magn Reson Imaging, 2025, 16(2): 51-58. DOI: 10.12015/issn.1674-8034.2025.02.008.
[18]
LIU N, WU Y K, TAO Y Y, et al. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma through MRI radiomics[J/OL]. Cancers, 2023, 15(22): 5373 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/38001633/. DOI: 10.3390/cancers15225373.
[19]
ZHANG C C, LU D, YANG J, et al. Clinical value and applicability of radiomics in differential diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J/OL]. World J Radiol, 2025, 17(6): 108247 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/40606043/. DOI: 10.4329/wjr.v17.i6.108247.
[20]
XU H Y, ZOU X H, ZHAO Y N, et al. Differentiation of intrahepatic cholangiocarcinoma and hepatic lymphoma based on radiomics and machine learning in contrast-enhanced computer tomography[J/OL]. Technol Cancer Res Treat, 2021, 20: 15330338211039125 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/34499018/. DOI: 10.1177/15330338211039125.
[21]
HENNEDIGE T, VENKATESH S K. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring[J]. Cancer Imaging, 2012, 12(3): 530-547. DOI: 10.1102/1470-7330.2012.0044.
[22]
DUPONT J, FRAU F, ROBIC V, et al. Beyond handcrafted radiomics in oncologic imaging: Innovations in deep, explainable, multi-site and multi-omics radiomics approaches[J]. Diagn Interv Imaging, 2026, 107(5): 165-178. DOI: 10.1016/j.diii.2026.02.001.
[23]
ZHOLSHYBEK N, BASTARBEKOVA L. Harmonizing multicenter quantitative imaging data: sources of variability, statistical solutions, and practical workflows in CT and MRI[J/OL]. Explor Digit Health Technol, 2026, 4: 101185 [2026-02-08]. https://www.explorationpub.com/Journals/edht/Article/101185. DOI: 10.37349/edht.2026.101185.
[24]
PARMAR C, RIOS VELAZQUEZ E, LEIJENAAR R, et al. Robust Radiomics feature quantification using semiautomatic volumetric segmentation[J/OL]. PLoS One, 2014, 9(7): e102107[2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/25025374/. DOI: 10.1371/journal.pone.0102107.
[25]
ZHONG J Y, LIU X W, LU J J, et al. Overlooked and underpowered: a meta-research addressing sample size in radiomics prediction models for binary outcomes[J]. Eur Radiol, 2025, 35(3): 1146-1156. DOI: 10.1007/s00330-024-11331-0.
[26]
LITVIN A A, BURKIN D A, KROPINOV A A, et al. Radiomics and digital image texture analysis in oncology (review)[J]. Sovrem Tekhnologii Med, 2021, 13(2): 97-104. DOI: 10.17691/stm2021.13.2.11.
[27]
ZHANG X, BAI Q M, WANG Y L, et al. FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH[J]. Virchows Arch, 2025, 487(5): 1103-1115. DOI: 10.1007/s00428-025-04067-9.
[28]
LIAO H T, CHEN X, WANG H C, et al. Whole-genome DNA methylation profiling of intrahepatic cholangiocarcinoma reveals prognostic subtypes with distinct biological drivers[J]. Cancer Res, 2024, 84(11): 1747-1763. DOI: 10.1158/0008-5472.can-23-3298.
[29]
GOYAL L, MERIC-BERNSTAM F, HOLLEBECQUE A, et al. Futibatinib forFGFR2-rearranged intrahepatic cholangiocarcinoma[J]. N Engl J Med, 2023, 388(3): 228-239. DOI: 10.1056/nejmoa2206834.
[30]
GENOVESI V, SALANI F, RIMINI M, et al. Molecular profiling and matched targeted treatment in cholangiocarcinoma: Results from the Italian dataset (ANITA)[J]. J Hepatol, 2026, 84(5): 933-945. DOI: 10.1016/j.jhep.2025.12.016.
[31]
VIGANÒ L, ZANUSO V, FIZ F, et al. CT-based radiogenomics of intrahepatic cholangiocarcinoma[J]. Dig Liver Dis, 2025, 57(1): 118-124. DOI: 10.1016/j.dld.2024.06.033.
[32]
ZHANG M, YANG H, WAN L F, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 73(5): 1118-1130. DOI: 10.1016/j.jhep.2020.05.039.
[33]
ZHU C B, MA J Q, ZHU K, et al. Spatial immunophenotypes predict clinical outcome in intrahepatic cholangiocarcinoma[J/OL]. JHEP Rep, 2023, 5(8): 100762 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37360908/. DOI: 10.1016/j.jhepr.2023.100762.
[34]
CAI Z L, YANG H T, YU Z R, et al. Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials[J/OL]. World J Surg Oncol, 2024, 22(1): 295 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37360908/. DOI: 10.1186/s12957-024-03579-z.
[35]
DE SANTIS A, ZHU L, TAO J X, et al. Molecular subtypes of intrahepatic cholangiocarcinoma[J]. Trends Mol Med, 2025, 31(8): 755-769. DOI: 10.1016/j.molmed.2025.01.008.
[36]
ZHU Y, MAO Y F, CHEN J, et al. Value of contrast-enhanced CT texture analysis in predicting IDH mutation status of intrahepatic cholangiocarcinoma[J/OL]. Sci Rep, 2021, 11: 6933 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/33767315/. DOI: 10.1038/s41598-021-86497-4.
[37]
ZEN Y. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities[J]. Hum Pathol, 2023, 132: 197-207. DOI: 10.1016/j.humpath.2022.06.001.
[38]
MARTIN-SERRANO M A, KEPECS B, TORRES-MARTIN M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications[J]. Gut, 2023, 72(4): 736-748. DOI: 10.1136/gutjnl-2021-326514.
[39]
MAKAWITA S, LEE S, KONG E, et al. Comprehensive immunogenomic profiling of IDH1-/2-altered cholangiocarcinoma[J/OL]. JCO Precis Oncol, 2024, 8: e2300544[2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/38547421/. DOI: 10.1200/PO.23.00544.
[40]
ZHU A X, MACARULLA T, JAVLE M M, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7(11): 1669-1677. DOI: 10.1001/jamaoncol.2021.3836.
[41]
LIN J, DAI Y T, SANG C, et al. Multimodule characterization of immune subgroups in intrahepatic cholangiocarcinoma reveals distinct therapeutic vulnerabilities[J/OL]. J Immunother Cancer, 2022, 10(7): e004892[2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/35863823/. DOI: 10.1136/jitc-2022-004892.
[42]
ZHANG J, WU Z R, ZHAO J, et al. Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival[J]. Eur Radiol, 2021, 31(6): 3661-3672. DOI: 10.1007/s00330-020-07524-y.
[43]
JI G W, XU Z G, LIU S C, et al. Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target[J]. Clin Mol Hepatol, 2025, 31(3): 935-959. DOI: 10.3350/cmh.2024.0895.
[44]
CHEN B, MAO Y C, LI J C, et al. Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: a multi-institutional study[J/OL]. Comput Biol Med, 2023, 167: 107612 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37939408/. DOI: 10.1016/j.compbiomed.2023.107612.
[45]
JOB S, RAPOUD D, DOS SANTOS A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma[J]. Hepatology, 2020, 72(3): 965-981. DOI: 10.1002/hep.31092.
[46]
BOERNER T, DRILL E, PAK L M, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444. DOI: 10.1002/hep.31829.
[47]
GELFER R, GULLA A, KALVIN H L, et al. KRAS variants are associated with survival outcomes and genomic alterations in biliary tract cancers[J/OL]. JCO Precis Oncol, 2024, 8: e2400263[2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/39642327/. DOI: 10.1200/PO.24.00263.
[48]
PENG J B, FANG S, LI M S, et al. Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis[J/OL]. Open Life Sci, 2023, 18(1): 20220652 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/37483430/. DOI: 10.1515/biol-2022-0652.
[49]
SIA D, HOSHIDA Y, VILLANUEVA A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology, 2013, 144(4): 829-840. DOI: 10.1053/j.gastro.2013.01.001.
[50]
HE X, XIE S D, JIA C C, et al. Precision targeted-immunotherapy for BRAF V600E and MET-amplified biliary tract cancer: two case reports[J/OL]. Oncologist, 2025, 30(12): oyaf374 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/41396681/. DOI: 10.1093/oncolo/oyaf374.
[51]
QIAN X L, LU X, MA X J, et al. A multi-parametric radiomics nomogram for preoperative prediction of microvascular invasion status in intrahepatic cholangiocarcinoma[J/OL]. Front Oncol, 2022, 12: 838701 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/35280821/. DOI: 10.3389/fonc.2022.838701.
[52]
JANG H J, KIM D H, CHOI S H, et al. Preoperative prediction of microvascular invasion in intrahepatic cholangiocarcinoma and its prognostic implications: a multicenter study[J]. Liver Cancer, 2026, 15(1): 63-76. DOI: 10.1159/000547071.
[53]
XIANG F, WEI S M, LIU X Y, et al. Radiomics analysis of contrast-enhanced CT for the preoperative prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma[J/OL]. Front Oncol, 2021, 11: 774117 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/34869018/. DOI: 10.3389/fonc.2021.774117.
[54]
ZHOU Y, ZHOU G F, ZHANG J L, et al. Radiomics signature on dynamic contrast-enhanced MR images: a potential imaging biomarker for prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma[J]. Eur Radiol, 2021, 31(9): 6846-6855. DOI: 10.1007/s00330-021-07793-1.
[55]
MA X J, QIAN X L, WANG Q, et al. Radiomics nomogram based on optimal VOI of multi-sequence MRI for predicting microvascular invasion in intrahepatic cholangiocarcinoma[J]. La Radiol Med, 2023, 128(11): 1296-1309. DOI: 10.1007/s11547-023-01704-8.
[56]
MIAO G Y, QIAN X L, ZHANG Y F, et al. An MRI-based radiomics model for preoperative prediction of microvascular invasion and outcome in intrahepatic cholangiocarcinoma[J/OL]. Eur J Radiol, 2025, 183: 111896 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/39732135/. DOI: 10.1016/j.ejrad.2024.111896.
[57]
ZHANG S T, HUANG S Y, HE W, et al. Radiomics-based preoperative prediction of lymph node metastasis in intrahepatic cholangiocarcinoma using contrast-enhanced computed tomography[J]. Ann Surg Oncol, 2022, 29(11): 6786-6799. DOI: 10.1245/s10434-022-12028-8.
[58]
CHEN P Y, YANG Z W, NING P G, et al. To accurately predict lymph node metastasis in patients with mass-forming intrahepatic cholangiocarcinoma by using CT radiomics features of tumor habitat subregions[J/OL]. Cancer Imaging, 2025, 25(1): 19 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/40011960/. DOI: 10.1186/s40644-025-00842-8.
[59]
QIAN X L, NI X Y, MIAO G Y, et al. Association between MRI-based radiomics features and regional lymph node metastasis in intrahepatic cholangiocarcinoma and its clinical outcome[J]. Magnetic Resonance Imaging, 2025, 61(2): 997-1010. DOI: 10.1002/jmri.29477.
[60]
PAN Y J, WU S J, ZENG Y, et al. Intra- and peri-tumoral radiomics based on dynamic contrast enhanced-MRI to identify lymph node metastasis and prognosis in intrahepatic cholangiocarcinoma[J]. Magnetic Resonance Imaging, 2024, 60(6): 2669-2680. DOI: 10.1002/jmri.29390.
[61]
PARK J E, PARK S H. Uncover this tech term: tumor habitat analysis[J/OL]. Korean J Radiol, 2026, 27(5): 495 [2026-02-08]. https://pubmed.ncbi.nlm.nih.gov/41974531/. DOI: 10.3348/kjr.2026.0082.

PREV Progress of MRI-based radiomics in predicting aggressive phenotypes and evaluating individualized treatment decisions for hepatocellular carcinoma
NEXT Research progress on preoperative prediction of endometrial carcinoma molecular subtypes based on MRI radiomics and deep learning
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn